Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...

To win back power, Democrats must organize themselves against oligarchy—and that means rejecting the latest shoddy centrist ...

Growth is a milestone for any law firm, but expansion requires more than increased case volume. Hiring new attorneys, adding ...

This article originally appeared on Inside Climate News, a nonprofit, non-partisan news organization that covers climate, ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Aitson is a recovery navigator for Diversion Hub, a nonprofit that serves Oklahomans impacted by the criminal legal system. There, he spends his days with people who've been accepted into Oklahoma ...

Before we go, let us clarify, just in case – submitting a paper that was produced by a machine from A to Z is taboo. You’re ...